Molecular Imaging and Precision Medicine : PET/Computed Tomography and Therapy Response Assessment in Oncology - 28/11/17

Doi : 10.1016/j.cpet.2016.08.002

Sara Sheikhbahaei, MD, MPH ^a, Esther Mena, MD ^a, Puskar Pattanayak, MD ^a, Mehdi Taghipour, MD ^a, Lilja B. Solnes, MD ^a, Rathan M. Subramaniam, MD, PhD, MPH ^a,^b,^c,^d,^e,^⁎
^a Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Johns Hopkins University, 601 North Caroline Street, Baltimore, MD 21287, USA
^b Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
^c Department of Clinical Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
^d Department of Biomedical Engineering, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
^e Advanced Imaging Research Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA

^∗Corresponding author. Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390.Department of RadiologyUniversity of Texas Southwestern Medical Center5323 Harry Hines BoulevardDallasTX75390

Résumé

A variety of methods have been developed to assess tumor response to therapy. Standardized qualitative criteria based on 18F-fluoro-deoxyglucose PET/computed tomography have been proposed to evaluate the treatment effectiveness in specific cancers and these allow more accurate therapy response assessment and survival prognostication. Multiple studies have addressed the utility of the volumetric PET biomarkers as prognostic indicators but there is no consensus about the preferred segmentation methodology for these metrics. Heterogeneous intratumoral uptake was proposed as a novel PET metric for therapy response assessment. PET imaging techniques will be used to study the biological behavior of cancers during therapy.

Le texte complet de cet article est disponible en PDF.

Keywords : Molecular imaging, Precision medicine, PET/computed tomography, Therapy response, Oncology

Plan

Key points

Introduction

Quantitative PET therapy response assessment criteria

Standardized qualitative PET therapy response assessment criteria

Lugano Classification

Hopkins Criteria

Immune-related Response Criteria

Novel PET metrics for therapy response assessment

Future trends

Disclosure: Dr E. Mena is supported by NIBI/NIH under the award number T32EB006351. Drs S. Sheikhbahaei, P. Pattanayak, M. Taghipour, L.B. Solnes, and R.M. Subramaniam have nothing to disclose.

Export

Vol 12 - N° 1

P. 105-118 - janvier 2017 Retour au numéro

Article précédent

Radionuclide Therapies in Molecular Imaging and Precision Medicine
A. Tuba Kendi, Valeria M. Moncayo, Jonathon A. Nye, James R. Galt, Raghuveer Halkar, David M. Schuster

| Article suivant

Molecular Imaging and Precision Medicine in Dementia and Movement Disorders
Atul K. Mallik, Alexander Drzezga, Satoshi Minoshima

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Molecular Imaging and Precision Medicine : PET/Computed Tomography and Therapy Response Assessment in Oncology - 28/11/17

Résumé

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL